Hospira filed two petitions for inter partes review of Genentech’s U.S. Patent 7,371,379 (IPR2017-00805) and U.S. Patent 6,627,196 (IPR2017-00804).  According to the petitions, these patents are directed to methods of treating certain cancers with trastuzumab, sold under the name Herceptin®.  These petitions follow closely on the heels of three petitions that Hospira filed on two other Genentech patents related to trastzumab, as we previously reported.

The petitions for these two IPRs and other important IPR filings on biologics are posted to our IPR tracker page.